Jun. 17 2011
Source Page: Registration of primary medical services to providers with the Care Quality Commission: a consultation on a proposed change to the date of registration. Consultation paper. 12 p.Found: Registration of primary medical services to providers with the Care Quality Commission: a consultation
Mar. 15 2011
Source Page: Table showing Department of Health consultations launched since 2002 onwards, and their duration.Found: Table showing Department of Health consultations launched since 2002 onwards, and their duration.
Asked by: Claire Hanna (Social Democratic & Labour Party - Belfast South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department plans to undertake a (a) review of and (b) public consultation on the Vaccine Damage Payment Scheme.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
All routine policy, including the Vaccine Damage Payment Scheme (VDPS), is reviewed on a regular basis. My Rt hon. Friend, the Secretary of State for Health and Social Care is currently looking into aspects of the scheme, following recent meetings with interested stakeholders.
Separately, work is underway with the scheme’s administrator, the NHS Business Service Authority, to review processes and make administrative changes, to improve the scheme within the current legislative framework. Formal consideration of whether any reforms to the VDPS are necessary will form part of Module 4 of the COVID-19 Inquiry, chaired by the Rt Hon Baroness Heather Carol Hallett DBE.
Apr. 23 2009
Source Page: Working to put people first: the strategy for the adult social care workforce in England. 60 p.Found: Working to put people first: the strategy for the adult social care workforce in England. 60 p.
Found: , 5 March 2021 21 Department of Health and Social Care, £79 million to boost mental health support
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps is she taking to review the decisions of the Medicines and Healthcare products Regulatory Agency.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care, under United Kingdom legislation, relating to the regulation of medicines, medical devices, and blood products for transfusion. The MHRA also performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care in relation to the standardisation and control of biological medicines including vaccines, blood products, and other substances which cannot be characterised chemically, and which require special testing measures to ensure their safety and efficacy.
My Rt hon. Friend, the Secretary of State for Health and Social Care has ministerial responsibility for, and oversight of, the MHRA’s delivery and performance. The MHRA seeks ministerial agreement for policy and legislative framework changes. Ministers are not involved in individual decisions made by the MHRA. The MHRA is held to account through regular established mechanisms including quarterly and annual accountability reviews. A framework agreement between the Department and the MHRA also sets out the governance structure within which both parties operate, with further information available at the following link:
The MHRA also publishes performance figures each month, as well as its annual report and accounts, and the minutes of the latest Annual Accountability Review with the MHRA is available at the following link:
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how the Medicines and Healthcare products Regulatory Agency is held accountable for its decisions.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care, under United Kingdom legislation, relating to the regulation of medicines, medical devices, and blood products for transfusion. The MHRA also performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care in relation to the standardisation and control of biological medicines including vaccines, blood products, and other substances which cannot be characterised chemically, and which require special testing measures to ensure their safety and efficacy.
My Rt hon. Friend, the Secretary of State for Health and Social Care has ministerial responsibility for, and oversight of, the MHRA’s delivery and performance. The MHRA seeks ministerial agreement for policy and legislative framework changes. Ministers are not involved in individual decisions made by the MHRA. The MHRA is held to account through regular established mechanisms including quarterly and annual accountability reviews. A framework agreement between the Department and the MHRA also sets out the governance structure within which both parties operate, with further information available at the following link:
The MHRA also publishes performance figures each month, as well as its annual report and accounts, and the minutes of the latest Annual Accountability Review with the MHRA is available at the following link:
Asked by: Caroline Lucas (Green Party - Brighton, Pavilion)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to her Department's Women's Health Strategy for England, published in August 2022, if she will publish a timeline for the commitments made to female same-sex couples on (a) intrauterine insemination and (b) IVF treatment in all integrated care boards.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
NHS England has made good progress in developing guidance to assist integrated care boards with implementing this policy commitment. The Department is working at pace with NHS England to share this guidance with the National Health Service. This commitment remains a priority for us in implementing the Women’s Health Strategy.
Asked by: Justin Madders (Labour - Ellesmere Port and Neston)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what her planned timescale is for rolling out the maternal morbidity indicator.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Department recognises the importance of monitoring near-misses and severe maternal morbidity, and continues to consider how a maternal morbidity indicator can be implemented. No timescales for a national rollout of the indicator have been set.
NHS England has developed 14 Maternal Medicine Networks (MMN) across England to ensure that all women with chronic and acute medical problems around pregnancy, for instance diabetes or heart disease, have access to specialist management and care from physicians and obstetrics, tackling the biggest contributors to maternal mortality. The Department is in the process of commissioning the National Institute for Health and Care Research’s Policy Research Unit for Maternal and Neonatal Health, to undertake research into developing an MMN-specific maternal morbidity outcome indicator, and provide the prevalence of current morbidity as a baseline for ongoing monitoring.
Dec. 12 2007
Source Page: Strategic review of Department of Health funding of third sector organisations: consultation paper. 56 p.Found: Strategic review of Department of Health funding of third sector organisations: consultation paper.